QRxPharma Initiates Second Comparative Study For MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY), a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain and central nervous system (CNS) disorders, announced today the initiation of a comparative 3-arm pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo(TM) IR (immediate release) capsules in patients who have undergone total knee replacement surgery.

More: continued here

Filed under: Pain / Anesthetics on February 25th, 2009